Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Toolkit Designed to Expand Resources for Genomic Research

By LabMedica International staff writers
Posted on 28 Aug 2013
Use of a new genotype/phenotype resource should help researchers better determine the links between genetics, disease, health, and the environment.

As part of a new award from the US National Human Genome Research Institute (Bethesda, MD, USA), RTI International (Research Triangle Park, NC, USA) will expand the PhenX Toolkit, a web-based resource that supports collaborative genomics and biomedical research. More...


The goals of the four-year, USD 5.3 million award, the genomic resource grant for PhenX Toolkit include updating and expanding the Toolkit, integrating Chinese and Spanish translations of PhenX protocols and mapping PhenX variables to all completed studies in the database of genotypes and phenotypes (dbGaP).

“This award gives the PhenX team the opportunity to address the evolving needs of the scientific community by enhancing the content and features of the Toolkit,” said Carol M. Hamilton, PhD, director of bioinformatics at RTI and PhenX lead investigator. “The use of PhenX measures increases the opportunities for researchers to combine or compare their findings, thus increasing the impact of each individual study.”

The PhenX Toolkit, a web-based catalog of 339 well-established measures of phenotypes and exposures, combines data from a range of research and allows investigators to enlarge a study design beyond the basic research focus. Enhancements to PhenX measurements will increase the overall impact of individual studies by making it easier to compare and combine data.

“The PhenX Toolkit is a great resource for investigators who would like to strategically expand their study design by adding a few standard measures,” Dr. Hamilton said. “Because common, complex diseases share many risk factors, identification of these factors increases with the use of common measures in research studies.”

PhenX is driven by the scientific community and decisions are reached using an established consensus process. Since 2007, the RTI-led PhenX project has engaged working groups of experts to select high-priority measures and a steering committee to provide guidance and policymaking decisions.

The PhenX Toolkit currently has more than 1,100 registered users and is publically available at no cost online (please see Related Links below).

Related Links:

RTI International
PhenX Toolkit



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.